Efficacy of radiofrequency ablation for papillary thyroid microcarcinoma in vietnam

Efficacy of radiofrequency ablation for

papillary thyroid microcarcinoma in Vietnam

Dr. Le Thi My ~ Thyroid center

Vinmec Times Cty Hospital

ne

I, BACKGROUND THERMAL ABLATION FOR PIMC

{VINMEC

MINIMIIĐML

4 THyrold cancer Number of new cases in 2020, both sexes, all ages

Mh most common cancer In: 2
(nan Ma:
0 “400.000 new cases/yea (on the worl), VN “E000 new cases HHT————————ưu
Man.
{eat We =—— SHU)
(ti
0 P5854 thyroid cancer 1s papllary carcinoma type (good
prognosis time survival 25-30 years) tal a)
nl cat 37713
$y tic Meanomao sin lự
Own
0 PIMC ‘is a thyroid cancer with small tumors that are 1.0 em ‘al, corrervoalstem
(ay I TS

maximum in dlameter wth WHO defination)~ T2NOMO Malte elon 1h
Nà
Gulblader
bóng i Thyroid
Jun WH
Aint A) Source: Globocan 2020
Tess Bh
m.: ) IWWW !ÿWWW 00000)
WM 61
Ps 3008
lrlgt0 [1N
luI\lm |3!)
Vagna [0

l #WW

A fy

\ l

Neck tension Voice $WÚùUQ — HH \

and tenderness problems pURU ©» windpipe

Hematoma Decreased parathyroid Recurent lrynge
hormone activity nerve injury

Background

th NEIM 20

Theoden

j 4 incidence /

3

8 1i ' /' | lnllteý

i ty fala tod
ane

ThuroidCancer Incidence and Related Mortal in South Korea, 1953-201,

{VINMEC Thyroid Carcnoma, Version 2.2022

PMO

\NúUIt'

FMA AGNOSTIC PREOPERATIVE OR PRIMARY TREATMENT
RESULTS PROCEDURES TRAOPERATIVE
DECISION-MAKING CRITERIA
cansor
|oltlly opnh.
| Phy andrc urs] Kw itl mete
|Mhihjewhlud ( Lfh@ddlulaln
‘wal compari),no) f+ Tuenn aalanl
ry ate ceclympohde
} CMR! wth conrasfor ‘metaosr tpoas sceesna

lcaly add dae || cnn ete
hen op | Poorly
louliuwuuuel |Cnprt raton
rol cadntty ||| agargay
iMeeituldidted | \ }* Cofo bnlrtnodal

}Fined asprinNA)
{or suspicious trl ach

yo and ck usd =e

\obactony!

Coynph cnots)a—— Mang acpmy bv]

rine

Mal ru

hu

Therevised clinical practice guidelines onthe
managemofethnyrtoid tumors bythe Japan

Associations ofndorin Surgeons: Core questions and

recommefnor tdreaatmtenitsoofnthysroid cancer

Yt Nay Ono? and Taio hav th Tsk Fuse of he pn Asin of

Eden Sugth Celinnohyo Tumors

Table} Risesof PC

Rik Desnipn

Nia lok THNOMO

Lại ——_TIONOMO

Hens pee

Hig — MladowdflkilUUuy

IÏlm

2)extn thrid ekasion aunt
stu yp forthe seid vài ,
us tlre i
A ra hop mt) Í

3c naa ts ow W
ul
Supresion
|——

2047 Thyroid Radiofrequency Ablation Guideline: Korean

Society of Thyroid Ratilogy

Joo in, MD, Pangan Bek, MD PA?Hyun jung Lin MD, Hye hin Ab, MO,

Seo Baek, MD; Yoon JungCo HO’, Youn Jun Chi PA”, Se Rom Cun, HD,

tunJt HO Sort in a), Oa Sk Ki, HD",

Syn din in, HO" Yeo Koo in, HD",hyi Yo i JegHn Le, D, PD,

Avant a, HO a ti KA egSeo ak, PAD,HenPa, Mm

Sdn Hee Shin, MD, PD! CongHyun ub MO’, Yong Sung, MO ung Sok Sin, MD, PD
Inttu Youn, MO, PH, yungCho PAD, dong Gu Na, MO, PHD": Guitn mnie

forthe Noa Soy of Thr Ratology (THR) and Korean Society of atlogy

Key Quen 3 ha the adeno Ro Key Question 2) Wha Ane the ndeaton for REA fo

Pinay Thyroid Cancers? Recurrent Thyroid Cancers?

Saray sa standard treatment opin thy thid_(Reconmendtio2n}

cance Tee ations fo Ro pina Ratorequeney alain a eprmed fo cutor

cash et en eat ead Hoe in plate purposes in the ecurenttcanhceyiatdhe

pis wth pinay ty cancer whofe suey or lhyilelom ad and cervical gh notefso patsat
bih sual ir vhost,
wh cannot undergo an open, thamal btn canbe
considered as an alteratve, Recent, RF, laser tation coat ude q,ty eer

(Ua lowe tina eaten

patents wth papilay tod micocarcinoa (FTA),

OW

nea

Guldelines

tu hel ON
ON SNS

European Thyroid Association and Cardiovascular [TUYITTIYYITT
and Interventional Radological Society of Europe

2001 Clinical Practice Guideline forthe Use of

Minimally Invasive Treatments in Malignant

DICin the follwing lun se Sexaninton

1, PIMC Syedade li

a Unresectable thyroidcancer Nowe fetal ead Potion aon

ý Teal ove Palin

4, Neckympnohde recurences of DIC pin pian \lnhhr pụt

4, Distant metastases Estrada ead

Irdtultnuw

Hada

NAT moa na tran MCA, pop tyro! ican, rand

VPIMNO{MEC

2023 European Thyroid Association Clinical Meda

Practice Guidelines for thyroid nodule management (A) Check fr upd

SSL

eee rere ree |

Ho” 0 210) 10L 2009)0/00/711000)1)

q0 1/00/0100 20) 10/11)

PAN ARP a A « BethesVdaand VI

lui DJ + Al nodes, regardless of EUTIRADS as: ecommend sugary"

MA HA

bu) Âu) | Active survelance and MIT may be considered inpatients with 5-10mm

nodules,nthe absence of suslcous lymph nodeosr isk of extra

thyroidal extension!

+ Multidiscpinary workup is warrinacasne otf aedvadnced cancer

[Strength of ecmmendatin 1; quality of evidence: 00. Agreement: (8.9) rund:

J

US-Guided Radiofequency Ablation fr Low-Risk
Papilary Thyroid Micocarcinomas Eficay and Safety
ina Large Population

Hun Kung Lin, HO", Se Jn Cho, MD, dung Han ae, MDP’, on le Le, MD, Pd’,

Crag Ho Son MO’ ung in Son, MD, Sen Wi Bae, MO

Ohjetv: To erate the fayand say caioequeny ablation (RA) for ows papla hyo mcocacnona
(PIMC) ina lage population,

Materials an Nett: Cases of 152 bap proven PTAC rom 13 patents who fad undergone RFA for PHC betven

Nh 2008 and January 2017 were included inthis stud, Al patients were etherof high surgical ko refed to undergo
surgery, They wee lowed up fr at least 6 months after nta FA, Urasonagaphy (1) and conputedtonogaphy ere
permed to vate the PTAC andthe presence of neck tats bee treatment, RFA was conducted ing an intl
cooled tyrit-deticated eletode system Follow-up US was permed at week, and 6, and 12 mnths, fer the ntl
AAA, ad the at eve 6-12 nn, We vate sel cangs fated tum, ey developed cance, mph ode (.)

or distant metastasainsd complains,

Rests Glee apace Wa od 91445 (18)/152) fated Ut, Anon the 13 unosin pats who did

nntshow complete dsgpearace, no tumor layed ary rego ofthe xual ablated sion uring the flow-up period

The ean flow-yp pid was 39 months, During the flow-p eid, were Q Oa cROL Gdisk

[IMBlfl and no nen) developed thrid cance, No patents wee feed to suger, The ove conpcaton at was

5% 4/133) of patients, including one voice change, There were no fe-treateing complications or pocedureelated
deaths,
Cnliston Gur eats sugges that FAs an effective ad safe option or teatng lows PTC patents who are of igh
surgical isk ores sure,

European Radiology (202) 31085-684

htp/1d0.10l07 SoO033r0-0g000/71286

ULTRASOUND \

Check for

Long tem outcomes ofradoequanblcatyion for unifocal lowsisk “”P
papillary thyroid microarcnoma; a large cohort study
of 414 patients

LinYan!Y,uan’ dng Mao”Lin in? Ma lăng: lu

From June 2014 fo Dec, 2017, 414 pts, (328 females, 91 males, mean age 43,56 +
9.79 year, range 18-73 years)

¥ Amean VAR of 98.81 + 6.41% (range 50-100), a FU time of 42,15 + 11,88 months

range 24-69 months) 366 tumors (88.41%) completely disappeared,

¥No complications occurred,

j

II DI 3|3(Í

Very Low risk PTMC
1, Papillary carcinoma type,

2, Sma¢ltlem,
3, No lymphonode metastasis? > US, CT, PET

4, Safety margin: from nerve, vessel, trachea, capsule

Best selection

VINMEC

Ensue that the safety magni ager than 3mm oneah plane Local Anesthesia

ofthe (Safety marg2 i3mnm + Trans= isthmic approach

` Hydrodssection technique

+ Fixed technique
* Moving-shot technique

Ge ae]

REA tips for PTMC

ne

I, BACKGROUND THERMAL ABLATION FOR PIMC

Result of RFA for PTMC at Vinmec hospi

SO Ug | ow |

Nbrof PIMC 1W

Mean age 0113/24)

[amltlMit đI

Mean Ft) 954 153-30)

ean les ameter (nn) $541(22-10)
Mean volun (al) II ‡6(IWWHI7)

Ti of ablation rood) 534189(2+ 0)

Te average tuo disappear) 4 nots

Loa tum protssion I

Local eewrence I

Newt developed thrid cancers (Cae rant voce change = recone

Lymph nodes metas fe week and | nth)

Conan